Seroconversion Following COVID-19 Vaccination in Patients with Multiple Myeloma (MyVax)
Summary
In this study, patients with multiple myeloma will be tested to see how well the vaccine against COVID-19 has worked. It is recommended that all patients with myeloma receive a vaccine against COVID-19 after discussing this with their physician. But there is very little information available about how well COVID-19 vaccines work in patients with myeloma. Myeloma patients can have decreased immune function and in the effectiveness of vaccines due to the disease and the treatments that patients receive.
This study will include patients with multiple myeloma who plan to be vaccinated for COVID-19 or who have recently been vaccinated. It will look for the antibodies that develop in response to COVID-19 vaccine or infection. A blood sample looking for antibodies against COVID-19 will be taken before the first dose of vaccine, and again 4 weeks after vaccination is complete. If antibodies are found, participants will be retested after 3 months and 6 months to see how long the antibodies last.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 18 to 100
Inclusion criteria:
To be included, participants will:
1. Be at least 18 years old
2. Have with a diagnosis of multiple myeloma, smoldering myeloma, or systemic amyloidosis
3. Have received or plan to receive a vaccine for COVID-19.
Exclusion criteria:
Patients will not be eligible if they are unable to have complete course of vaccination, or cannot receive a COVID-19 vaccine for any reason.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
Patients can be referred to this study by their physician or by contacting Dr. Peter Duggan
Principal investigator:
Peter Duggan
Clinical trial:
No
REB-ID:
HREBA.CC-21-0078